Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
396 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016', provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) - The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects - The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Graft Versus Host Disease (GVHD) Overview 11 Therapeutics Development 12 Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 12 Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 13 Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 14 Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 19 Graft Versus Host Disease (GVHD) - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Graft Versus Host Disease (GVHD) - Products under Development by Companies 25 Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 30 Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 31 AbbVie Inc 31 AbGenomics International, Inc. 32 Actelion Ltd 33 Alexion Pharmaceuticals Inc 34 Amunix Operating Inc. 35 Apceth GmbH & Co. KG 36 arGEN-X BV 37 Athersys, Inc. 38 Bellicum Pharmaceuticals, Inc. 39 Bio-Cancer Treatment International Limited 40 Biogen Inc 41 Bristol-Myers Squibb Company 42 Cantex Pharmaceuticals, Inc. 43 Capricor Therapeutics, Inc. 44 Cell2B S.A. 45 CellECT Bio, Inc. 46 Cynata Therapeutics Limited 47 Cytodyn Inc. 48 Dompe Farmaceutici S.p.A. 49 Dr. Falk Pharma GmbH 50 Escape Therapeutics, Inc. 51 F. Hoffmann-La Roche Ltd. 52 Fate Therapeutics, Inc. 53 Generon (Shanghai) Corporation Ltd. 54 Gilead Sciences, Inc. 55 GlaxoSmithKline Plc 56 Idera Pharmaceuticals, Inc. 57 ImmuNext, Inc. 58 Immunomedics, Inc. 59 Incyte Corporation 60 Kadmon Corporation, LLC 61 Kamada Ltd. 62 Kiadis Pharma N.V. 63 Kymab Limited 64 Kyorin Pharmaceutical Co., Ltd. 65 MacroGenics, Inc. 66 Mallinckrodt Plc 67 Medsenic 68 Mesoblast Limited 69 Millennium Pharmaceuticals Inc 70 Neopharm Ltd. 71 Nohla Therapeutics Inc. 72 Novartis AG 73 OncoImmune, Inc. 74 OSE Immunotherapeutics 75 Pharmicell Co., Ltd. 76 REGiMMUNE Corporation 77 Rigel Pharmaceuticals, Inc. 78 Sarepta Therapeutics, Inc. 79 Seattle Genetics, Inc. 80 Seres Therapeutics, Inc. 81 Sigmoid Pharma Limited 82 Spherium Biomed S.L. 83 Takeda Pharmaceutical Company Limited 84 Targazyme, Inc. 85 Therapix Biosciences Ltd. 86 Tobira Therapeutics, Inc. 87 Vault Pharma Inc. 88 Xenikos B.V. 89 ZIOPHARM Oncology, Inc. 90 Graft Versus Host Disease (GVHD) - Therapeutics Assessment 91 Assessment by Monotherapy Products 91 Assessment by Combination Products 92 Assessment by Target 93 Assessment by Mechanism of Action 97 Assessment by Route of Administration 101 Assessment by Molecule Type 103 Drug Profiles 105 abatacept - Drug Profile 105 AbGn-168H - Drug Profile 110 AGS-499 - Drug Profile 112 aldesleukin - Drug Profile 113 Alecmestencel-L - Drug Profile 115 alpha-1 proteinase inhibitor (human) - Drug Profile 116 ALXN-1007 - Drug Profile 120 AMX-342 - Drug Profile 122 anti-thymocyte globulin (rabbit) - Drug Profile 123 Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 125 Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 126 ARGX-115 - Drug Profile 127 arsenic trioxide - Drug Profile 128 ATIR-101 - Drug Profile 129 BCT-200 - Drug Profile 133 begelomab - Drug Profile 134 Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 135 Biologics for Graft Versus Host Disease - Drug Profile 136 bortezomib - Drug Profile 137 BPX-501 - Drug Profile 145 brentuximab vedotin - Drug Profile 149 budesonide - Drug Profile 173 cannabidiol - Drug Profile 176 CAP-2003 - Drug Profile 177 CD-24Fc - Drug Profile 178 Cell Therapy for Graft Versus Host Disease - Drug Profile 179 Cell Therapy for Graft-Versus Host Disease - Drug Profile 180 Cellgram for Graft Versus Host Disease - Drug Profile 181 Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 182 Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 183 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 185 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 186 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 187 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 188 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 189 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 190 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 191 Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 192 cenicriviroc mesylate - Drug Profile 193 CRCBT-080004 - Drug Profile 200 CX-01 - Drug Profile 201 cyclosporine CR + cyclosporine IR - Drug Profile 203 CYP-001 - Drug Profile 204 entospletinib - Drug Profile 206 F-652 - Drug Profile 208 FR-104 - Drug Profile 209 Ha-7 - Drug Profile 212 ibrutinib - Drug Profile 213 ImmuneSafe - Drug Profile 238 ImmuStem - Drug Profile 239 IMO-8400 - Drug Profile 240 IT-603 - Drug Profile 246 IT-901 - Drug Profile 247 itacitinib adipate - Drug Profile 248 KD-025 - Drug Profile 251 KRP-203 - Drug Profile 255 KY-1005 - Drug Profile 257 MAX-16H5 - Drug Profile 258 MesoStem - Drug Profile 259 methoxsalen - Drug Profile 260 MGD-010 - Drug Profile 262 milatuzumab - Drug Profile 264 Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 266 natalizumab - Drug Profile 268 nilotinib - Drug Profile 272 obinutuzumab - Drug Profile 278 OCU-300 - Drug Profile 285 Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 286 panobinostat - Drug Profile 287 PF-05285401 - Drug Profile 295 ponesimod - Drug Profile 305 Preimplantation Factor - Drug Profile 307 PRO-140 - Drug Profile 308 ProTmune - Drug Profile 316 R-348 - Drug Profile 318 Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 320 Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 321 Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 322 remestemcel-L - Drug Profile 323 reparixin - Drug Profile 328 RGI-2001 - Drug Profile 331 RO-2959 - Drug Profile 333 rovalpituzumab tesirine - Drug Profile 334 ruxolitinib phosphate - Drug Profile 336 S-Graft - Drug Profile 347 SER-155 - Drug Profile 348 Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 349 Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile 350 Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 351 Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 352 sonidegib phosphate - Drug Profile 353 SP-12008 - Drug Profile 357 SYGN-305 - Drug Profile 358 Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 359 T-Guard - Drug Profile 360 TZ-101 - Drug Profile 362 vedolizumab - Drug Profile 365 VPI-101 - Drug Profile 369 ZL-1101 - Drug Profile 370 Graft Versus Host Disease (GVHD) - Dormant Projects 371 Graft Versus Host Disease (GVHD) - Discontinued Products 376 Graft Versus Host Disease (GVHD) - Product Development Milestones 377 Featured News & Press Releases 377 Appendix 388 Methodology 388 Coverage 388 Secondary Research 388 Primary Research 388 Expert Panel Validation 388 Contact Us 388 Disclaimer 389
List of Tables
Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016 19 Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Number of Products under Development by Companies, H2 2016 (Contd..2) 23 Number of Products under Development by Companies, H2 2016 (Contd..3) 24 Number of Products under Development by Companies, H2 2016 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2016 27 Comparative Analysis by Late Stage Development, H2 2016 28 Comparative Analysis by Clinical Stage Development, H2 2016 29 Comparative Analysis by Early Stage Development, H2 2016 30 Comparative Analysis by Unknown Stage Development, H2 2016 31 Products under Development by Companies, H2 2016 32 Products under Development by Companies, H2 2016 (Contd..1) 33 Products under Development by Companies, H2 2016 (Contd..2) 34 Products under Development by Companies, H2 2016 (Contd..3) 35 Products under Development by Companies, H2 2016 (Contd..4) 36 Products under Investigation by Universities/Institutes, H2 2016 37 Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2016 38 Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2016 39 Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2016 40 Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 41 Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc. , H2 2016 42 Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2016 43 Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H2 2016 44 Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2016 45 Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 46 Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 47 Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2016 48 Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2016 49 Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 50 Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics, Inc., H2 2016 51 Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2016 52 Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H2 2016 53 Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H2 2016 54 Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H2 2016 55 Graft Versus Host Disease (GVHD) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 56 Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016 57 Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2016 58 Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 59 Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H2 2016 60 Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 61 Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences, Inc., H2 2016 62 Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2016 63 Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 64 Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2016 65 Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2016 66 Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H2 2016 67 Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2016 68 Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2016 69 Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma N.V., H2 2016 70 Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2016 71 Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 72 Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2016 73 Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H2 2016 74 Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H2 2016 75 Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2016 76 Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 77 Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2016 78 Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc., H2 2016 79 Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2016 80 Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H2 2016 81 Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H2 2016 82 Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2016 83 Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2016 84 Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 85 Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2016 86 Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2016 87 Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H2 2016 88 Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2016 89 Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2016 90 Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 91 Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2016 92 Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd., H2 2016 93 Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2016 94 Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc., H2 2016 95 Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2016 96 Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 97 Assessment by Monotherapy Products, H2 2016 98 Assessment by Combination Products, H2 2016 99 Number of Products by Stage and Target, H2 2016 101 Number of Products by Stage and Mechanism of Action, H2 2016 105 Number of Products by Stage and Route of Administration, H2 2016 109 Number of Products by Stage and Molecule Type, H2 2016 111 Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2016 378 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2016 379 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2016 380 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2016 381 Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H2 2016 382 Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2016 383
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
